tiprankstipranks
Neurocrine Biosciences (NBIX)
NASDAQ:NBIX
US Market
NBIX
Neurocrine
RESEARCH TOOLSreports
Want to see NBIX full AI Analyst Report?

Neurocrine (NBIX) Stock Forecast & Price Target

1,578 Followers
See the Price Targets and Ratings of:

NBIX Analyst Ratings

Strong Buy
22Ratings
Strong Buy
19 Buy
3 Hold
0 Sell
Based on 22 analysts giving stock ratings to
Neurocrine
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NBIX Stock 12 Month Forecast

Average Price Target

$187.00
▲(40.34% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is $187.00 with a high forecast of $246.00 and a low forecast of $144.00. The average price target represents a 40.34% change from the last price of $133.25.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"105":"$105","176":"$176","247":"$247","140.5":"$140.5","211.5":"$211.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":246,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$246.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":187,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$187.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":144,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$144.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[105,140.5,176,211.5,247],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.78,140.56615384615384,149.3523076923077,158.13846153846154,166.92461538461538,175.71076923076924,184.49692307692308,193.28307692307692,202.06923076923078,210.85538461538462,219.64153846153846,228.42769230769233,237.21384615384616,{"y":246,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.78,136.02769230769232,140.2753846153846,144.52307692307693,148.77076923076925,153.01846153846154,157.26615384615386,161.51384615384615,165.76153846153846,170.00923076923078,174.25692307692307,178.5046153846154,182.75230769230768,{"y":187,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.78,132.72,133.66,134.6,135.54,136.48,137.42,138.36,139.3,140.24,141.18,142.12,143.06,{"y":144,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":106.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.63,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.38,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.56,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.78,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$246.00Average Price Target$187.00Lowest Price Target$144.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on NBIX
Cory Kasimov
Evercore ISI
Evercore ISI
$210
Buy
57.60%
Upside
Reiterated
05/18/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham Analyst forecast on NBIX
Ami Fadia
Needham
Needham
$200
Buy
50.09%
Upside
Reiterated
05/11/26
Neurocrine (NBIX) Gets a Buy from Needham
BMO Capital Analyst forecast on NBIX
Evan Seigerman
BMO Capital
BMO Capital
$144
Hold
8.07%
Upside
Reiterated
05/11/26
Analysts' Top Healthcare Picks: Neurocrine (NBIX), Certara (CERT)
RBC Capital Analyst forecast on NBIX
Nevin Varghese
RBC Capital
RBC Capital
$180
Buy
35.08%
Upside
Assigned
05/11/26
RBC Capital Sticks to Their Buy Rating for Neurocrine (NBIX)
J.P. Morgan Analyst forecast on NBIX
Anupam Rama
J.P. Morgan
J.P. Morgan
$177→$185
Buy
38.84%
Upside
Assigned
05/08/26
J.P. Morgan Keeps Their Buy Rating on Neurocrine (NBIX)
Deutsche Bank Analyst forecast on NBIX
David Hoang
Deutsche Bank
Deutsche Bank
$150→$155
Hold
16.32%
Upside
Reiterated
05/07/26
Neurocrine price target raised to $155 from $150 at Deutsche BankNeurocrine price target raised to $155 from $150 at Deutsche Bank
Truist Financial Analyst forecast on NBIX
Danielle Brill
Truist Financial
Truist Financial
$155
Buy
16.32%
Upside
Assigned
05/07/26
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Fresenius Medical Care (NYSE: FMS) and American Well (NYSE: AMWL)
Guggenheim Analyst forecast on NBIX
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$175
Buy
31.33%
Upside
Reiterated
05/06/26
Neurocrine (NBIX) Receives a Buy from Guggenheim
Oppenheimer Analyst forecast on NBIX
Jay Olson
Oppenheimer
Oppenheimer
$220→$230
Buy
72.61%
Upside
Assigned
05/06/26
Neurocrine price target raised to $230 from $220 at OppenheimerNeurocrine price target raised to $230 from $220 at Oppenheimer
Stifel Nicolaus Analyst forecast on NBIX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$188
Buy
41.09%
Upside
Reiterated
05/06/26
Neurocrine (NBIX) Gets a Buy from Stifel Nicolaus
Piper Sandler Analyst forecast on NBIX
David Amsellem
Piper Sandler
Piper Sandler
$190→$207
Buy
55.35%
Upside
Reiterated
05/06/26
Neurocrine (NBIX) Gets a Buy from Piper Sandler
Morgan Stanley Analyst forecast on NBIX
Sean Laaman
Morgan Stanley
Morgan Stanley
$185→$191
Hold
43.34%
Upside
Reiterated
05/06/26
Neurocrine Biosciences: Hold Maintained as Analyst Lifts Price Target to $191 Amid Strong Ingrezza Demand and Pipeline Execution Risks
Citi Analyst forecast on NBIX
Yigal Nochomovitz
Citi
Citi
$242→$246
Buy
84.62%
Upside
Assigned
05/06/26
Neurocrine price target raised to $246 from $242 at CitiNeurocrine price target raised to $246 from $242 at Citi
Canaccord Genuity Analyst forecast on NBIX
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$200
Buy
50.09%
Upside
Reiterated
05/06/26
Canaccord Genuity Keeps Their Buy Rating on Neurocrine (NBIX)
William Blair Analyst forecast on NBIX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/05/26
NBIX: Strong Crenessity and Ingrezza Outperformance, Robust 2026 Outlook and Pipeline Catalysts Underpin Buy Rating
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on NBIX
Cory Kasimov
Evercore ISI
Evercore ISI
$210
Buy
57.60%
Upside
Reiterated
05/18/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham Analyst forecast on NBIX
Ami Fadia
Needham
Needham
$200
Buy
50.09%
Upside
Reiterated
05/11/26
Neurocrine (NBIX) Gets a Buy from Needham
BMO Capital Analyst forecast on NBIX
Evan Seigerman
BMO Capital
BMO Capital
$144
Hold
8.07%
Upside
Reiterated
05/11/26
Analysts' Top Healthcare Picks: Neurocrine (NBIX), Certara (CERT)
RBC Capital Analyst forecast on NBIX
Nevin Varghese
RBC Capital
RBC Capital
$180
Buy
35.08%
Upside
Assigned
05/11/26
RBC Capital Sticks to Their Buy Rating for Neurocrine (NBIX)
J.P. Morgan Analyst forecast on NBIX
Anupam Rama
J.P. Morgan
J.P. Morgan
$177→$185
Buy
38.84%
Upside
Assigned
05/08/26
J.P. Morgan Keeps Their Buy Rating on Neurocrine (NBIX)
Deutsche Bank Analyst forecast on NBIX
David Hoang
Deutsche Bank
Deutsche Bank
$150→$155
Hold
16.32%
Upside
Reiterated
05/07/26
Neurocrine price target raised to $155 from $150 at Deutsche BankNeurocrine price target raised to $155 from $150 at Deutsche Bank
Truist Financial Analyst forecast on NBIX
Danielle Brill
Truist Financial
Truist Financial
$155
Buy
16.32%
Upside
Assigned
05/07/26
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Fresenius Medical Care (NYSE: FMS) and American Well (NYSE: AMWL)
Guggenheim Analyst forecast on NBIX
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$175
Buy
31.33%
Upside
Reiterated
05/06/26
Neurocrine (NBIX) Receives a Buy from Guggenheim
Oppenheimer Analyst forecast on NBIX
Jay Olson
Oppenheimer
Oppenheimer
$220→$230
Buy
72.61%
Upside
Assigned
05/06/26
Neurocrine price target raised to $230 from $220 at OppenheimerNeurocrine price target raised to $230 from $220 at Oppenheimer
Stifel Nicolaus Analyst forecast on NBIX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$188
Buy
41.09%
Upside
Reiterated
05/06/26
Neurocrine (NBIX) Gets a Buy from Stifel Nicolaus
Piper Sandler Analyst forecast on NBIX
David Amsellem
Piper Sandler
Piper Sandler
$190→$207
Buy
55.35%
Upside
Reiterated
05/06/26
Neurocrine (NBIX) Gets a Buy from Piper Sandler
Morgan Stanley Analyst forecast on NBIX
Sean Laaman
Morgan Stanley
Morgan Stanley
$185→$191
Hold
43.34%
Upside
Reiterated
05/06/26
Neurocrine Biosciences: Hold Maintained as Analyst Lifts Price Target to $191 Amid Strong Ingrezza Demand and Pipeline Execution Risks
Citi Analyst forecast on NBIX
Yigal Nochomovitz
Citi
Citi
$242→$246
Buy
84.62%
Upside
Assigned
05/06/26
Neurocrine price target raised to $246 from $242 at CitiNeurocrine price target raised to $246 from $242 at Citi
Canaccord Genuity Analyst forecast on NBIX
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$200
Buy
50.09%
Upside
Reiterated
05/06/26
Canaccord Genuity Keeps Their Buy Rating on Neurocrine (NBIX)
William Blair Analyst forecast on NBIX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/05/26
NBIX: Strong Crenessity and Ingrezza Outperformance, Robust 2026 Outlook and Pipeline Catalysts Underpin Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

3 Months
Tazeen AhmadBank of America Securities
Success Rate
18/25 ratings generated profit
72%
Average Return
+4.82%
Copying Tazeen Ahmad's trades and holding each position for 3 Months would result in 72.00% of your transactions generating a profit, with an average return of +4.82% per trade.
1 Year
Tazeen AhmadBank of America Securities
Success Rate
19/25 ratings generated profit
76%
Average Return
+9.91%
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 76.00% of your transactions generating a profit, with an average return of +9.91% per trade.
2 Years
Tazeen AhmadBank of America Securities
Success Rate
23/25 ratings generated profit
92%
Average Return
+19.86%
Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 92.00% of your transactions generating a profit, with an average return of +19.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NBIX Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
1
7
7
10
7
Buy
41
45
29
27
24
Hold
4
5
4
6
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
46
57
40
43
39
In the current month, NBIX has received 31 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. NBIX average Analyst price target in the past 3 months is 187.00.
Each month's total comprises the sum of three months' worth of ratings.

NBIX Financial Forecast

NBIX Earnings Forecast

Next quarter’s earnings estimate for NBIX is $1.56 with a range of $1.11 to $2.18. The previous quarter’s EPS was $1.91. NBIX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.
Next quarter’s earnings estimate for NBIX is $1.56 with a range of $1.11 to $2.18. The previous quarter’s EPS was $1.91. NBIX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.

NBIX Sales Forecast

Next quarter’s sales forecast for NBIX is $866.70M with a range of $825.30M to $929.20M. The previous quarter’s sales results were $814.50M. NBIX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.
Next quarter’s sales forecast for NBIX is $866.70M with a range of $825.30M to $929.20M. The previous quarter’s sales results were $814.50M. NBIX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.

NBIX Stock Forecast FAQ

What is NBIX’s average 12-month price target, according to analysts?
Based on analyst ratings, Neurocrine Biosciences’s 12-month average price target is 187.00.
    What is NBIX’s upside potential, based on the analysts’ average price target?
    Neurocrine Biosciences has 40.34% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NBIX a Buy, Sell or Hold?
          Neurocrine Biosciences has a consensus rating of Strong Buy which is based on 19 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Neurocrine Biosciences’s price target?
            The average price target for Neurocrine Biosciences is 187.00. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $246.00 ,the lowest forecast is $144.00. The average price target represents 40.34% Increase from the current price of $133.25.
              What do analysts say about Neurocrine Biosciences?
              Neurocrine Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of NBIX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.